Gestational Diabetes: Risk or Myth?
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
There is a wide spectrum of views regarding the clinical significance of the entity known as gestational diabetes mellitus (GDM). At one end of the spectrum are advocates of strict evidence-based medical care who argue that there is insufficient evidence for preventable morbidity resulting from asymptomatic maternal hyperglycemia during pregnancy to warrant routine detection and treatment of GDM. At the other end are advocates of universally strict glycemic control during pregnancy. They argue that even minimal maternal hyperglycemia is potentially dangerous and worthy of detection and aggressive treatment. As is often the case when such wide ranging views abound, truth and prudence seem to lie somewhere between the extremes. There is evidence that asymptomatic hyperglycemia during pregnancy is attended by important morbidity in the mother and offspring; at least some of the morbidity can be reduced by detection and treatment of GDM. However, over the range of glycemia generally encountered in GDM, only a subset of women and their infants are at risk for morbidity related to maternal hyperglycemia. Ignoring all asymptomatic hyperglycemia during pregnancy will result in inattention to important morbidities in the population. Aggressive detection and treatment of even minimal hyperglycemia during pregnancy will lead to unnecessary overtreatment of many women. The logical solution to this dilemma is the development of methods to stratify patients with GDM, regarding perinatal and long-term health risks, so that treatments can be tested and applied in the highest risk cases. The emphasis of this commentary will be on measures that can be taken in that regard. There is quite firm evidence that increasing maternal glycemia during pregnancy is associated with an increasing risk of clinically important morbidity in infants. The most obvious evidence comes from women with established diabetes, whose infants suffer an increased risk of congenital anomalies, in proportion to maternal glycemia, during the first trimester and an increased risk of several perinatal complications, in proportion to maternal glycemia, during later pregnancy. These problems are not limited to women with diagnosed diabetes. At least one cross-sectional study of women with hyperglycemia first detected during pregnancy revealed that presentation with a fasting serum glucose more than 120 mg/dL was associated with a doubling of the risk of congenital anomalies in newborns (1). Blinded (2) and unblinded (3) evaluations of maternal glucose levels during the latter half of pregnancy have revealed a fairly slow and continuous increase in complications, like macrosomia and cesarean delivery, as maternal glucose levels rise in the subdiabetic range. These findings indicate that rising maternal glycemia should be viewed as a risk factor for adverse perinatal outcomes. There may be a glucose threshold above which the risk of congenital anomalies increases sharply in early pregnancy, but there does not seem to be any such threshold for complications related to excess fetal nutrition and overgrowth in later pregnancy. Thus, maternal glycemia cannot be used to discriminate clearly between low and high risks for late-pregnancy complications, which are the major concern in GDM. The continuous relation between maternal glycemia and macrosomia-related perinatal risks accounts for much of the controversy in the diagnosis and management of GDM. Without a biological threshold for risk, there can be no proof of a superior set of diagnostic criteria or therapeutic guidelines based on maternal glucose alone. One of three general approaches can be taken: 1) set a low and very sensitive glucose threshold for identifying at-risk pregnancies and treat all patients who exceed that threshold; 2) set a very high and insensitive threshold and treat only patients who exceed it; or 3) set a low glucose threshold and, among women who exceed it, use additional information to identify patients at high or low risk when making decisions about monitoring and treatment. The first approach has been taken by advocates of universally strict glycemic control during pregnancy. They have shown that it is possible to eliminate the 10–20% excess risk of complications such as fetal macrosomia in women with diagnosed GDM, by having all patients perform capillary glucose monitoring and by administering insulin to the 50–70% of patients whose glucose exceeds very strict postprandial glucose thresholds. The fraction of women treated with this approach is generally quite high, compared with the fraction of pregnancies in which morbidity is prevented. Nonetheless, this approach has been reported to be cost effective in one retrospective analysis (4). The cost effectiveness of this approach may decrease as glucose thresholds for diagnosing GDM are lowered (5), resulting in more low-risk women being given the diagnosis. The second approach, of setting a high threshold for abnormality, is essentially
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although gestational diabetes mellitus is a recognized marker for an increased risk of subsequent diabetes, its clinical significance with respect to various adverse pregnancy outcomes has been uncertain.2,4”
From A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes (2009) · cites this paper as [4]
Experimental — accuracy not yet measured
Citations
Cites
Metzger, B. E., Buchanan, T. A., Coustan, D. R., de Leiva, A., Dunger, D. B., Hadden, D. R., Hod, M., Kitzmiller, J. L., Kjos, S. L., Oats, J. N., et al. (2007) · Diabetes Care · doi:10.2337/dc07-s225 · Cited by 1,908
Self-citationSermer, M., Naylor, C. D., Gare, D. J., Kenshole, A. B., Ritchie, J. W. K., Farine, D., Cohen, H. R., McArthur, K., Holzapfel, S., Biringer, A., et al. (1995) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(95)90183-3 · Cited by 510
Long-term prospective evaluation of offspring of diabetic mothers
Silverman, B. L., Rizzo, T., Green, O. C., Cho, N. H., Winter, R. J., Ogata, E. S., Richards, G. E., & Metzger, B. E. (1991) · Diabetes · doi:10.2337/diab.40.2.s121 · Cited by 452
Kjos, S. L., Peters, R. K., Xiang, A., Henry, O. A., Montoro, M., & Buchanan, T. A. (1995) · Diabetes · doi:10.2337/diab.44.5.586 · Cited by 356
Self-citationGestational diabetes and perinatal mortality rate
O'Sullivan, J. B., Charles, D., Mahan, C. M., & Dandrow, R. V. (1973) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(16)33834-0 · Cited by 297
Diabetes and Obesity in the Offspring of Pima Indian Women With Diabetes During Pregnancy
Pettitt, D. J., Nelson, R. G., Saad, M. F., Bennett, P. H., & Knowler, W. C. (1993) · Diabetes Care · doi:10.2337/diacare.16.1.310 · Cited by 295
Peters, R. K., Xiang, A., Kjos, S. L., & Buchanan, T. A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90405-5 · Cited by 273
Self-citationToward universal criteria for gestational diabetes: the 75-gram glucose tolerance test in pregnancy
Sacks, D. A., Greenspoon, J. S., Abu-Fadil, S., Henry, H. M., Wolde-Tsadik, G., & Yao, J. F. F. (1995) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(95)90580-4 · Cited by 210
Buchanan, T. A., Kjos, S. L., Montoro, M. N., Wu, P. Y. K., Madrilejo, N. G., Gonzalez, M., Nunez, V., Pantoja, P. M., & Xiang, A. (1994) · Diabetes Care · doi:10.2337/diacare.17.4.275 · Cited by 186
Self-citationParity and incidence of non-insulin-dependent diabetes mellitus
Manson, J. E., Rimm, E. B., Colditz, G. A., Stampfer, M. J., Willett, W. C., Arky, R. A., ROSNER, B. A., Hennekens, C. H., & Speizer, F. E. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90674-z · Cited by 94
Cited by
A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes
Landon, M. B., Spong, C. Y., Thom, E., Carpenter, M. W., Ramin, S. M., Casey, B., Wapner, R. J., Varner, M. W., Rouse, D. J., Thorp, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902430 · Cited by 2,122
Developmental Origins of the Metabolic Syndrome: Prediction, Plasticity, and Programming
Mcmillen, I. C., & Robinson, J. S. (2005) · Physiological Reviews · doi:10.1152/physrev.00053.2003 · Cited by 1,910
Lindström, J., & Tuomilehto, J. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.725 · Cited by 1,862
Gestational diabetes: The consequences of not treating
Langer, O., Yogev, Y., Most, O., & Xenakis, E. M. J. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.11.039 · Cited by 677
An overview of pediatric obesity
Lee, W. W. R. (2007) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00337.x · Cited by 103
Metadata
- Authors
- Buchanan, T. A., & Kjos, S. L.
- Affiliations
- University of Southern California (US)
- Corresponding author
- Buchanan, Thomas A.
- ORCID
- Buchanan, Thomas A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1999-06
- Volume
- 84
- Issue
- 6
- Pages
- 1854-1857
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W4254685230
- Cited by
- 23
- References
- 11
- Citations by year
- 2012: 4
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Keywords
- gestational diabetes mellitus, maternal hyperglycemia, glycemic control, risk stratification, congenital malformations, perinatal complications, macrosomia, cesarean section, overtreatment, glycemic thresholds, fetal hypoglycemia, fetal growth restriction, fetal hypoxia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gestational Diabetes: Risk or Myth? https://app.cochat.ai/papers/10.1210/jc.84.6.1854
- The paper
- Buchanan, T. A., & Kjos, S. L. (1999). Gestational Diabetes: Risk or Myth? The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.84.6.1854
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.